Oscar Health, Inc. (OSCR) Q4 2025 Earnings Call February 10, 2026 8:00 AM EST
Company Participants
Chris Potochar – Vice President of Treasury & Investor Relations
Mark Bertolini – CEO & Director
Richard Blackley – Chief Financial Officer
Conference Call Participants
Joshua Raskin – Nephron Research LLC
Jessica Tassan – Piper Sandler & Co., Research Division
Jonathan Yong – UBS Investment Bank, Research Division
John Ransom – Raymond James & Associates, Inc., Research Division
Stephen Baxter – Wells Fargo Securities, LLC, Research Division
Samuel Becker – Goldman Sachs Group, Inc., Research Division
Raj Kumar – Stephens Inc., Research Division
Craig Jones – BofA Securities, Research Division
Presentation
Operator
Good morning. My name is Jeannie, and I will be your conference operator today. At this time, I would like to welcome everyone to Oscar Health’s Fourth Quarter and Full Year 2025 Earnings Conference Call. [Operator Instructions] I will now turn the call over to Chris Potochar, Vice President of Treasury and Investor Relations.
Chris Potochar
Vice President of Treasury & Investor Relations
Good morning, everyone. Thank you for joining us for our fourth quarter and full year 2025 earnings call. Mark Bertolini, Oscar Health’s Chief Executive Officer; and Scott Blackley, Oscar Health’s Chief Financial Officer, will host this morning’s call. This call can also be accessed through our Investor Relations website at ir.hioscar.com. Full details of our results and additional management commentary are available in our earnings release which can be found on our Investor Relations website at ir.hioscar.com. Any remarks that Oscar makes about the future constitute forward-looking statements within the meaning of safe harbor provisions under the Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those indicated by those forward-looking statements as a result of various important factors, including those discussed in our quarterly report on Form 10-Q for the period ended